Follow
Jiangeng Huang
Title
Cited by
Cited by
Year
Replication or exploration? Sequential design for stochastic simulation experiments
M Binois, J Huang, RB Gramacy, M Ludkovski
Technometrics 61 (1), 7-23, 2019
1502019
Analyzing stochastic computer models: A review with opportunities
E Baker, P Barbillon, A Fadikar, RB Gramacy, R Herbei, D Higdon, ...
Statistical Science 37 (1), 64-89, 2022
67*2022
Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after≥ 2 prior therapies: 3-year follow-up …
SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ...
Blood 142, 603, 2023
272023
On‐site surrogates for large‐scale calibration
J Huang, RB Gramacy, M Binois, M Libraschi
Applied Stochastic Models in Business and Industry 36 (2), 283-304, 2020
172020
Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter's transformation
CY Cheah, S Assouline, R Baker, NL Bartlett, D El-Sharkawi, P Giri, M Ku, ...
Blood 142, 614, 2023
112023
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib
M Shadman, JP Sharman, MY Levy, R Porter, SF Zafar, JM Burke, ...
Hematological Oncology 39, 2021
102021
NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma
RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Aoun, CM Bello, ...
J Natl Compr Canc Netw 12 (2), 2014
72014
CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple …
R Vij, H Schade, S Trudel, AC Chang, J Huang, D Samineni, T Sumiyoshi, ...
J. Clin. Oncol 40, 16, 2022
62022
Zanubrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory (R/R) follicular lymphoma (FL)
CS Tam, H Quach, A Nicol, X Badoux, H Rose, HM Prince, MF Leahy, ...
Hematological Oncology 37, 121-122, 2019
62019
Multi-output calibration of a honeycomb seal via on-site surrogates
J Huang, RB Gramacy
Technometrics 64 (4), 548-563, 2022
52022
A frequentist approach to dynamic borrowing
R Li, R Lin, J Huang, L Tian, J Zhu
Biometrical Journal 65 (7), 2100406, 2023
32023
Safety and activity of the highly specific BTK inhibitor, BGB-3111 plus obinutuzumab in patients (PTS) with follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
CS Tam, H Quach, A Nicol, X Badoux, H Rose, H Prince, MF Leahy, ...
Hematol Oncol 35, 113, 2017
22017
PB2034: CAMMA 1: A Multicenter phase IB trial evaluating the safety, pharmacokinetics and activity of cevostamab-containing regimens in patients with relapsed or refractory …
R Vij, H Schade, S Trudel, AC Chang, J Huang, D Samineni, T Sumiyoshi, ...
HemaSphere 6 (Suppl), 1905-1906, 2022
12022
PB1890: zanubrutinib in acalabrutinib-intolerant patients (PTS) with B-cell malignancies
M Shadman, IW Flinn, EC Kingsley, B Freeman, MY Levy, J Cultrera, ...
HemaSphere 6, 1769-1770, 2022
12022
CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory …
S Delimpasi, H Quach, M Cavo, PJ Ho, C Lee, A Santoro, R Schots, ...
J. Clin. Oncol 40, 16, 2022
12022
Sequential learning, large-scale calibration, and uncertainty quantification
J Huang
Virginia Tech, 2019
12019
Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse …
M Ozcan, WS Kim, H Zhang, M Bouzani, Z Nagy, H Chuah, G Salles, ...
Blood 144, 4502.1, 2024
2024
Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After≥ 2 Prior Therapies: 3-Year Follow-Up …
SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ...
Presented at the 12th Annual Meeting of the Society of Hematologic Oncology …, 2024
2024
IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After≥ 2 Prior Therapies: 3-Year …
SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ...
Clinical Lymphoma Myeloma and Leukemia 24, S497, 2024
2024
P-019 Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and …
T Jelinek, A Spencer, A Krishnan, S Trudel, S Harrison, M Breuleux, ...
Clinical Lymphoma Myeloma and Leukemia 23, S43, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20